TickerFacts.

Keros Therapeutics, Inc. (KROS): Capital Expenditures

Annual figures by period end, from SEC filings.

$1.55M
Year ended 2025-12-31
$494.0K
Trailing 12 months to 2026-06-30
+7.7%
3-year compound annual growth
+39.5%
5-year compound annual growth
$2.46M2019-12-31: $271.0K2020-12-31: $294.0K2021-12-31: $1.02M2022-12-31: $1.24M2023-12-31: $2.46M2024-12-31: $1.93M2025-12-31: $1.55M$1.55M
2019-12-31 Capital Expenditures (USD) 2025-12-31
Period endedCapital ExpendituresChange YoYSource filing
2025-12-31$1.55M-19.7%2026-03-04, From 2025-01-01
2024-12-31$1.93M-21.6%2026-03-04, From 2024-01-01
2023-12-31$2.46M+98.5%2025-02-26, From 2023-01-01
2022-12-31$1.24M+21.2%2025-02-26, From 2022-01-01
2021-12-31$1.02M+248.3%2024-02-28, From 2021-01-01
2020-12-31$294.0K+8.5%2022-03-09, From 2020-01-01
2019-12-31$271.0Kn/a2021-03-25, From 2019-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCapital ExpendituresChange YoY
Keros Therapeutics, Inc. (KROS)2025-12-31$1.55M-19.7%
Arcus Biosciences, Inc. (RCUS)2025-12-31$2.00M-66.7%
Akebia Therapeutics, Inc. (AKBA)2025-12-31$291.0K+781.8%
Anaptysbio, Inc (ANAB)2025-12-31$87.0K-75.7%
Schrodinger, Inc. (SDGR)2025-12-31$1.44M-80.3%
Puma Biotechnology, Inc. (PBYI)2025-12-31$71.0K+26.8%
Arvinas, Inc. (ARVN)2025-12-31$1.90M+5.6%
Ligand Pharmaceuticals Inc (LGND)2025-12-31$452.0K-75.2%
Vireo Growth Inc. (VREOF)2025-12-31$28.32M+142.2%

Compare KROS, RCUS, AKBA, ANAB side by side · Screen every company in Pharmaceutical Preparations ↗